Hongbin Chen, MD, PhD | Authors


Afatinib for <em>EGFR</em> Mutation-Positive, Advanced Non-Small Cell Lung Cancer

November 11, 2013

Activating EGFR mutations are associated with response to TKIs. Afatinib (Gilotrif) is an oral, irreversible ErbB family TKI that targets EGFR, HER2, and ErbB4. Afatinib is being formally evaluated in the LUX-Lung clinical trial program for NSCLC.